Omeros Company Description

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.

The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.

It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder.

In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Immunostimulator Combination Therapies, and Oncotoxins and Immunomodulators for the treatment of various cancers.

Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Omeros Corporation

Country	United States
Founded	1994
Industry	Biological Products, Except Diagnostic Substances
Employees	202
CEO	Gregory Demopulos

Contact Details

Address: The Omeros Building Seattle, Washington 98119 United States
Phone	206 676 5000
Website	omeros.com

Stock Details

Ticker Symbol	3O8
Exchange	Frankfurt Stock Exchange
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Gregory Demopulos	Chief Executive Officer
David Borges	Chief Financial Officer